Search Results for "Ranbaxy Launches Atorvastatin In Us"

10:39 EDT 29th August 2015 | BioPortfolio

Matching Channels


Matching News

Atorvastatin/Ezetimibe beats atorvastatin after PCI

(HealthDay)—For Japanese patients who have undergone percutaneous coronary intervention (PCI), atorvastatin plus ezetimibe is associated with improved outcomes versus atorvastatin alone, according t...

With Ranbaxy Under Belt, Sun Eyes Fast Track Global Growth

Sun and Ranbaxy have finally combined into a single global company, but that could be just the beginning of a series of fresh challenges. Sun said it will look at growing its businesses faster than th...

Caution with Lipitor and boceprevir use

The summary of product characteristics for Lipitor (atorvastatin; Pfizer) now advises that patients who are concomitantly taking boceprevir should have a lower starting dose of atorvastatin and should...

Sun Pharma finally completes Ranbaxy acquisition

Indian generic drugmaker Sun Pharmaceutical Industries has at last completed the merger of Ranbaxy Laboratories…

Ranbaxy fails to reverse FDA decision over Valcyte and Nexium

Indian generics company Ranbaxy has yet again failed in its bid to become the first company in the US to sell generic versions of the AstraZeneca blockbuster acid-reflux drug Nexium (esomeprazole) and...

Daiichi Sankyo’s Subsidiary Ranbaxy merged with Sun Pharma

Biospectrum After this merger completion, Ranbaxy will be delisted from the Indian Stock Exchange [Read more]

Sun Pharma sacks 18 Ranbaxy executives

Sun Pharma has asked 18 executives to leave the company who were previously a part of Ranbaxy, the firm it acquired last year.  This huge India-based restructuring move reflects one of the bigges...

ANALYSIS: Will Sun-Ranbaxy Pairing Trigger More M&As In India?

The Indian pharmaceutical market is seeing a decisive shift. Starting now, Sun and Ranbaxy as a combined organization will dislodge Abbott from its top position held for over five years.

Matching PubMed Articles

Lipid-lowering efficacy of atorvastatin.

This represents the first update of this review, which was published in 2012. Atorvastatin is one of the most widely prescribed drugs and the most widely prescribed statin in the world. It is therefor...

Paradoxical effects of atorvastatin on renal tubular cells: an experimental investigation.

Atorvastatin has antioxidant activity and has been reported to increase blood antioxidant capacity. This study aimed to evaluate the effect of different doses of atorvastatin on gentamicin-induced kid...

Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population: Three-year clinical outcomes.

High dose atorvastatin is known to be associated with new onset diabetes mellitus (NODM) in patients with high risk for developing diabetes mellitus (DM). However, low dose atorvastatin is more common...

Physiologically Based Pharmacokinetic Modeling of Disposition and Drug-Drug Interactions for Atorvastatin and its Metabolites.

Atorvastatin is the most commonly used of all statins to lower cholesterol. Atorvastatin is extensively metabolized in both gut and liver to produce several active metabolites. The purpose of the pres...

The year's new drugs & biologics, 2014: Part I.

A year-end wrap-up of new drug approvals and launches reveals that activity in the pharmaceutical industry continues at a high level, with 55 new drugs and biologics introduced on their first markets ...

Search Whole site using Google


Advertisement Advertisement